tag:blogger.com,1999:blog-6278250556678332358Sun, 27 Nov 2011 23:18:10 +0000Flu seasonParkinson's Disease PychosisRPTPBSD MedicalSPPIChinainfraredRHHBFBioCrystLinjetaTodd GolubCardiomyocytesFV-100SmartMoneyEfavirenzStaph InfectionTenofovirSubstance abuseLung cancerRIGLBioPharma InvestmentsARNAFDA RecommendationDIJABIOSJCV-Antibody Assay10 Rules of Investing BioPharmaNorth CarolinaGardasilBioPharma BlogWall Street 2X-ray computed tomographyFDA DecisionsPhase 3Spectrum PharmaceuticalsDiagnostic TestingCeftarolineADCVaccineSanofi-AventisOnline advertisingWhat to do with 10AntiviralNasdaq CompositeAmerican Stock ExchangeEmergent BioSolutionsHopsiraMicroRNAPotential Market MoversHelicos BioSciencesGoogle Apple ChickBSD Medical CorporationInfluenza A virus subtype H5N1ILICYPBMedical EquipmentnanoparticleCerezymeMedical DeviceSciCloneTrubion PharmaceuticalsBeckman CoulterBRKRHindenburg OmenStock marketWashington PostType 2 DiabetesPerkinElmerHemispherx BioPharmaJohns HopkinsPrenatal TestingLupusCubist PharmaceuticalsMovie TrailerIntermezzoCBRXCPHIForest LaboratoriesYoutube VideoAlkermesBlood pressureMultiple Myeloma Research FoundationStock market crashKodroff and WillisFree DonationsStatinHRA PharmaGenentechLegacy of HopeMedicareVaxGenExact scienceCancer TreatmentsKey DevelopmentsAmgenKing PharmaceuticalsTSPTOlympia SnowePhase IIIMoney MagazineU.S. Food and Drug AdministrationBusinessGenlenyaBristol-Myers SquibbSchering-PloughAnti-obesity medicationApple IncAmerican Cancer SocietyPGNovo NordiskELNDepomedNational Institute of Allergy and Infectious DiseasesPfizer. LipitorBiologic License ApplicationFDA DecisionPlavixDEPONon-small cell lung carcinomaStockDebtor's RevoltCROProtalixHuman papillomavirusSuperbugsBiotechBecton DickinsonHepatitis C virusBioPharma Stock UpdatesMTDACUROnline Masters Degree ProgramsWall Street Stock CrashThe V FoundationGeneticsPittsburgh Post-GazetteSVAGlobeNewswireAlfred MannISCOCPIXAZNAllerganAntibiotic resistanceTalecris BiotherapeuticsPrimary immunodeficiencyWarren BuffettSafety IVHuluMagnetic resonance imagingJeremy SiegelAcetaminophenDown syndromeProtein-bound paclitaxelH1N1Teva Pharmaceutical IndustriesTMOGordon GekkoStem cellWhy It's Time To Be BullishClostridium difficileNASDAQJim CramerBig PharmaRobert Koch InstituteFDA ReviewCel-Sci Corp.trialsHSICPictures Of Bernie Madoff's Yacht'sTop Japanese BiopharmaPfizerALKSJazz PharmaceuticalTakeda Pharmaceutical CompanyNew Delhi metallo-beta-lactamaseAnit-bioticschemotherapyJimmy VPrescription Drug User Fee ActAntiretroviral drugHypotensionGeronHarry BoxerReturn on equityFRXACADInsulin TherapyOlivia Newton-JohnILMNPublic HealthTheStreetclinicalAlzheimer's TreatmentJanuary CatalystsAVNRFacet BiotechBioRunUpJulie RobertsCytokineticsRexahnPPHMHigh Risk Heart FailureBSDM FDA 510K Clearance MDX-180 BSD MedicalWeight lossNaltrexoneGeron CorporationKrystexxaSGENTranscept PharmaceuticalsPMLAlexza PharmaceuticalsYahooTLCRPharmaceuticalWeb Design and DevelopmentCyclacelFloxapenInfluenza researchMedical Device StocksAllayBenlystaMajor depressive disorderMens Cancer483 LetterLLYExact SciencesShireBlood ThinnerFast CrashSepracorBSDMInhalable insulinInfantile SpasmsWall Street: Money Never SleepsALXABiorunup.comMyriad GeneticsWarning Bear MarketLupus Foundation of AmericaSubstance dependenceQuestcor PharmaceuticalsMRKSpectorInfectionInfectious diseaseONXXOnko-SureCardium TherapeuticsMergers and AcquisitionsMike Havrilla Seeking Alpha BioMedReportsQGENNutra PharmaAMLNBrentuximab vedotinPFEEarnings Preview 3QBond BubbleABTInfluenza pandemicAnaplastic lymphoma kinaseTalecrisMorgantownHuman Genome ProjectRNA-dependent RNA polymeraseBRAFH1N1 StocksADA meetingLorcaserinInsulinAlcohol AddictionEscherichia coli O157:H7Biotech BlogAIDSVAXLife Technologies60 MinutesPotigaMcClellan OscillatorBankrupt NationMax BaucusBreaking NewsFDA PanelExchange-traded fundBoston ScientificBristol MyersWeekend at Bernie'sCYCCRaptor PharmaceuticalsBayerInfluenzaBlood cancerVivusVictozaDynPort VaccineSequenomVVUSIRSBStem cells. Embryonic stem cellReverse transcriptase inhibitorAfrezzaTransceptPhase III Clinical TrialsWeblogsGlaxo SmithKlineLeukemiaSLXPIdenixRXIIEndo PharmaceuticalsNational Institute on AgingellaBest Biotechnology BlogInstitute of Cancer ResearchEisaiMoney (magazine)Varicella Zoster VirusAZ-004 FDA RecommendationSanofi AventisStem CellsBeijing Genomics InstituteEXACAdsense AdsPatent Expiring 2011Proctor and GambleAIDSMelanomaAvian influenzaAMGNAmyotrophic lateral sclerosisSVNTSeattle GeneticsBioElectronics CorporationThe Medicines CompanyProvengeTop Performing Biotech Pharmaceuticals StocksBioPharmaceuticalsePROChina AnalystClass Action LawsuitDDDBMYHealthFacebookTop Metabolic DrugsSwine influenzaBlack MondayArena PharmaceuticalsNDM-1EarningsPimcoMad MoneyPharmaceutical drugIpilimumabBiovaxIDRadient PharmaceuticalOnglyzaGoogleLawsuitsAbbott LaboratoriesSQNMHuman Genome SciencesCelera GenomicsJZP-6ICGNOne Team One CauseSynthetic BiologyAmerican Diabetes AssociationAmerican Association for Cancer ResearchTop Biotechnology StocksCDCSwine Flu StocksEat Pray LoveWhat is MSRA?AlexionNon-Hodgkin's LymphomacancerMarketWatchBydureonCubicinProstate cancerHLCSHospiraIrritable bowel syndromeArQuleMark ZuckerbergMilliporeGamma-Hydroxybutyric acidTalecris IPOSwine Flu Outbreakcancer therapySavient PharmaceuticalCLDARigel PharmaceuticalsAlzheimernew 52-week lowsWVJ. Craig VenterWSJCELGJennifer AnistonBernie Madoff PropertyNVSHerpes ZosterBSPMChicken Pox VirusAntibiotic1987 Stock CrashSomaxon PharmaceuticalsArtificial gene synthesisAcute myeloid leukemiaMichael DouglasTags: BIIBStaccato SystemFDA Special Protocol AssessmentFibromyalgiaFDA Advisory PanelCellartisHead and neck cancerChronic myelogenous leukemiaPDL BioPharmaHuman Genome ScienceDrexel Burnham LambertEpilepsy DrugNewsmakers in the Biotech Industry ConferenceWilliam PrattImmunoGenPromotionBarack ObamaPancreatic cancerBioCenturyFederal Reserve SystemPfizer (PFE) and India's Ranbaxy Laboratories (RBXLF)JP Morgan Healthcare ConferenceEvaluatePharma 2014 forecastBristolAerocrineClinical trialSwine Flu HumorGilead Sciences3Q PreviewUnited States CongressReutersalliComputerized Drug DiscoverySNYExenatideBone metastasisBevacizumabMabCureErythromycinAVIICancer ResearchMillennium OncologyPatent ProtectionThe Next Wave of Medical MoneymakersVZVValtrexProfit marginObesity DrugsFDA CRLAQ197The StreeClass actionHCVNew DelhiBiogen IdecAastrom BiosciencesNarcolepsyBank of AmericaWall Street: Money Never SleepsResearch Triangle ParkSpherixBIODQ4 Drug ApprovalsWarren Buffett's Berkshire HathawayOnxyPKIDiabetes MedicationMannKind CorporationINX-189Breast cancerBernie Madoff YachtBernard MadoffDaiichi Sankyomelanoma drugBavituximabPain TherapiesMELA SciencesNSCLCmedicineBiolaseFinancial servicesObesityTranscription (genetics)Ariad PharmaceuticalQnexaMcAfeeNVAXPhase II Clinical TrialMedImmuneSpells Doom 52-week highsDUSAAZ-0042011 Biotech PreviewGalvusCellectisXOMADTop Biotechnology BlogCBSInfluenza A virus subtype H1N1RituxaniCADWhat Percentage Are Your Investments in One Stock?Induced Pluripotent Stem CellsDNAInterferon beta-1bXomatax revoltRaient PharmaceuticalsAvanirBuffalo NewsCystinosisDiabetes mellitusOpioid AddictionQCORDainippon Sumitomo PharmaHITKFailureMonoclonal antibodiesHEBNovaceaBrain CancerBDXDana–Farber Cancer InstituteOPXACancer VaccineSPEXLIFEAntibioticsCharles PonziPseudobulbar affect000 nowGlaxoSmithKlineGamunexMerckQuintiles White PapersEmbryonic stem cellShinglesCrohn's diseaseOXGNBristol Myers ZymoGenetics MergerCervical cancerSwine FluBiovailMylan PharmaceuticalMILDr. VenterLawfirmsFundraisingTylenolASTMCiproPrecious Metal DerivativesNon-steroidal anti-inflammatory drugProgressive multifocal leukoencephalopathySteve JobsCYTKColonoscopy ExamCurisUric acidDroxidopaVeralookSUNHWall Street JournalGoogle FinanceMDEANon-Hodgkin's lymphoma SPPI Spectrum PharmaceuticalsClinical DataVilazodoneMoney Never SleepsOncologyHodgkin lymphomaJC virusGSKHPVDiabetes mellitus type 1CelgenePradaxaSucampoLate Stage CancerPonzi schemeVirulent Skin GermsGenetic Engineering and Biotechnology NewsLaserMNKDSomaxonVirtual colonoscopyHPV cancerAnti-JC Virus AssayJimmy FallonWikInvestHelicosYahoo FinanceStem Cells InternationalBLTITakeda PharmaceuticalRosemanBristol-MyersCredit Card RantAbraxis BioScienceJazz PharmaceuticalsiStemAvanir STAR Clinical TrialRestless Leg Syndromegaucher diseaseBiotech 2011CotaraAlgetaTop Biotech StocksGreat DepressionNew England Journal of MedicinePeregrine PharmaceuticalsARYx TherapeuticsActharTrastuzumabIBSPresident ClintonRHHBYFlu ShotAcadia PharmaceuticalsZGENMasters Degree OnlineOptimer PharmaceuticalsHyperthermia Cancer TreatmentHGSIHoffmann–La RochePelpinCompugenFDA DelaysSteve KroftBond ETFsCancer DetectionBrain tumorAntibody-Drug ConjugatesPPCOPhase IITop Drug DevelopmentFundraiserRegenerative MedicineALIMTAArenaMelaFindSythetic GenomicVRXClinical TrialsEli LillyTroubled Asset Relief ProgramDDSSZymoGeneticsContraveFuture Biotech InnovationsCorporate BondsJohnson and JohnsonNanodrugsOSI PharmaceuticalsComplicated skin and skin structure infectionPsoriasisSpectrum Pharmaceuticals Added to the Russell Global(R)Rodman RenshawBiogenMutual Pharmaceutical CompanyDiamyd MedicalHuman GenomeTop Rated Stocks: BiotechnologyColorectal cancerMadoff's Property Up For AuctionChina Pharma HoldingsEquity Top PicksGenzymeDNEXReproCellISTA PharmaceuticalsVertex PharmaceuticalsBiodelPharmaceutical BlogRPCBCRXMultiple SclerosisNovavaxHPV vaccineGENCervarixAstellas PharmaMarcadia BiotechGenome StudyAVI BioPharmaMRSABiotechnology and PharmaceuticalsFDA approvalnanoshellMoodyMSGenericsEXAS3Q EarningsPharmaceutical industryLymphomaTruvadasearchSafety Syringe RevVacStocks for the Long RunEmtricitabineEmerging MarketsXGEVACannabis ScienceCritical Limb IschemiaAmylinPDLIMSRAMonoclonal antibodySilenorBioMarinprGCDRussell 3000(R) and Russell 2000(R) Indexes SPPIStocks and BondsProtalix BiotherapeuticsrafaximinGenerex BiotechStock CrashAllos TherapeuticsFDAHIV vaccineClinical Trial FailureBVFMichael MilkenBiopharmaceuticalFDA Drug Approvals ContestKGRare diseaseBioDelivery SciencesOREXSearch engineSolvay PharmaceuticalsChelsea TherapeuticsBiotechnology IndexPBT2Cancer Diagnostic TestDopey Cowboyscancer treatmentJimmy V LogoParkinsons DiseaseObesity DrugBiopharma InvestingWATEXELInvestingPharmaceuticalsGenerexRocheSystemic lupus erythematosusProstate-specific antigenGenetic disorderBristol-MeyersCancer Diagnostic TestingCRLIncretin PathwayGlioblastoma multiformeBroad InstituteSkystar BiopharmInfertilityDepressionMBCIEconomic Stimulus TARP MarketwatchCraig VenterHoward Hughes Medical InstituteCumberland PharmaceuticalsNew York Stock ExchangeJanuviaMillennium PharmaceuticalsCepheidCoca-ColaStaph AureusMedarexCorporate bondFDA rejectionBayer AGCancer DrugsGoutSOMXWhen Will The Recovery StartResearch and DevelopmentEuropean Society for Medical OncologyMYLVaccine ProductionINHXActiPatch deviceChinese BiopharmaceuticalsCTICMethicillin-resistant Staphylococcus aureusDNDNNon-small cell lung cancerWyethMikeHavRx.comCloud ComputingTKPHFMarket Snapshot Dow JonesNick Burns the Computer GuyDonationsForest LabsARIAGoogle GirlJapanese StocksDentistryThomson ReutersEscherichia coliARQLCancer ScreeningBiotech StocksTRBNSavient PharmaceuticalsOutbreakCHTPWall StreetForeign Bonds510KValeant PharmaceuticalOrexigen TherapeuticsElan CorporationDynPortGERNBIIBAlzheimer's diseaseJohnson N JohnsonCell TherapeuticsCystic FibrosisJNJBiovestViroproFood and Drug AdministrationXyremAdam FeuersteinOrexigen Therapeutics Inc.Valeant PharmaceuticalsAnacor PharmaceuticalsStock DeclinePimavanserinAmylin PharmaceuticalsSymptomatic Neurogenic Orthostatic HypotensionNovartisnanotechnologyBioCryst PharmaceuticalsCitigroupSKBIBiotech IPOPurdue PharmaceuticalsHeat Treatment for CancerMoody'sStock RallyDrug DiscoveryFood Drug AdministrationJ. Craig Venter InstituteActhar GelBaxterDVAXClick on the Ads PleaseHealth Care Billion Dollar Bill Drugmakers BioPharma MedicareColon CancerGirard BibbsFDA CalendarEli Lilly and CompanyAstraZenecaCrizotinibCypress BiosciencesPain managementVivitrolAntidepressantCancer Diagnostic ScreeningOpioid DependencePRXLCredit cardBiotechnology StocksCubist PharmaceuticsHIVNCSinovac BiotechGENZRevenueNew Drug ApplicationARYXDNA sequencingCellular DynamicsBioPharma Top PerformersTysabriDan Fusstype 1 diabetesTheravanceDenosumabJazzSt Jude MedicalEMSOInsomniaOliver StoneDow Jones Industrial AverageHPV Oral CancerThe SnowballInhibitexCVMBiologicsChinese BiotechDiagnostic ScreeningRoche Holding2010 Drug ApprovalsBerkshire HathawayManagement of cancerRheumatoid arthritisAMLBrentuximabPrana BiotechnologyJimmy ValvanoIMGNOvarian cancerBoehringer IngelheimCapriprazineALXNGermanyLegacy of Hope SocietyBelimumabPhentermine/topiramateHealth careFDA NewsHenry ScheinTop Performing BioPharma StocksBiotechnologyHi-Tech PharmacalTriusCytRxGenericKV.AGeneric DrugsSeeking AlphaSalix PharmaceuticalsRevolution MedicalBerkeley Software Distribution197DendreonJAZZ. PRANAddictionsBioPharma Investments ranging from Biotech, Pharmaceutical, & Medical Devices. Stocks in the Healthcare Sector. Top Stock Performers in a High Risk/High Reward Market. BioPharma Run-up Principles Based on Clinical Trial Recommendations by the FDA. Mergers and Acquisitions coverage. News from The Street and Jim Cramer MadMoney Picks. Stocks Based on Science not Hype. http://biopharmainvestor.blogspot.com/noreply@blogger.com (BioPharma Investor; Troubled Biologist)Blogger205125http://api.ning.com/files/cJ28FmSlfxiRzj0ujiA38GLM0ogQ9SQ3bOODr-gi0v8DyX4U8l8-gsGAOd30BDX92XmIKQvmh4IZwRLVdRipO4tYlaHiaOwi/BellRockLighthouseScotland.jpg?width=64&crop=1%3A1BioPharmaInvestorhttp://feedburner.google.comtag:blogger.com,1999:blog-6278250556678332358.post-8865256971354943494Sat, 09 Jul 2011 01:13:00 +00002011-07-08T21:15:39.151-04:00Steve KroftJ. Craig Venter InstituteArtificial gene synthesisCelera GenomicsDNACBSHuman Genome ProjectSynthetic BiologyCraig Venter60 MinutesImage via WikipediaJ. Craig Venter: Designing Life June 12, 2011 5:00 PM Steve Kroft profiles famous microbiologist J. Craig Venter, whose scientists have already mapped the human genome and created what he calls "the first synthetic species." Read more: http://www.cbsnews.com/video/watch/?id=7369820n&tag=cbsnewsMainColumnArea.8#ixzz1RZ052a3e (CBS News)  This story was first published on Novhttp://feedproxy.google.com/~r/BioPharmaInvestor/~3/2Q8EdDQ-m2s/60-minutes-on-j-craig-venter-designing_08.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/1PdbanRGtkj2ZIo1wu_g0QVLKLY/0/da"><img src="http://feedads.g.doubleclick.net/~a/1PdbanRGtkj2ZIo1wu_g0QVLKLY/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/1PdbanRGtkj2ZIo1wu_g0QVLKLY/1/da"><img src="http://feedads.g.doubleclick.net/~a/1PdbanRGtkj2ZIo1wu_g0QVLKLY/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=2Q8EdDQ-m2s:LULUXU0_30o:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=2Q8EdDQ-m2s:LULUXU0_30o:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=2Q8EdDQ-m2s:LULUXU0_30o:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=2Q8EdDQ-m2s:LULUXU0_30o:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=2Q8EdDQ-m2s:LULUXU0_30o:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=2Q8EdDQ-m2s:LULUXU0_30o:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=2Q8EdDQ-m2s:LULUXU0_30o:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=2Q8EdDQ-m2s:LULUXU0_30o:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=2Q8EdDQ-m2s:LULUXU0_30o:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/2Q8EdDQ-m2s" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/07/60-minutes-on-j-craig-venter-designing_08.htmltag:blogger.com,1999:blog-6278250556678332358.post-1687301607045268797Thu, 30 Jun 2011 13:13:00 +00002011-06-30T09:13:17.423-04:00AmgenCurisLate Stage CancerClinical TrialschemotherapyRochePfizerOnxyAriad PharmaceuticalCancer TreatmentscancerBristol-MeyersImage via WikipediaFrom FierceBiotech For the cancer drug research enthusiast, this report might read in places like a special oncology edition of a gun magazine. Indeed, there are plenty of weapons against cancer to read about here. Several of the drugs listed here represent the advancement of relatively new methods of attacking cancer, including "armed antibodies" and cancer-killing http://feedproxy.google.com/~r/BioPharmaInvestor/~3/a0UmmbPrvTI/cancer-clinical-trials-and-treatments.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/WQ736aAcPDKw7OmvU5j_QWwSKxM/0/da"><img src="http://feedads.g.doubleclick.net/~a/WQ736aAcPDKw7OmvU5j_QWwSKxM/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/WQ736aAcPDKw7OmvU5j_QWwSKxM/1/da"><img src="http://feedads.g.doubleclick.net/~a/WQ736aAcPDKw7OmvU5j_QWwSKxM/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=a0UmmbPrvTI:fBbmrch4q4w:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=a0UmmbPrvTI:fBbmrch4q4w:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=a0UmmbPrvTI:fBbmrch4q4w:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=a0UmmbPrvTI:fBbmrch4q4w:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=a0UmmbPrvTI:fBbmrch4q4w:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=a0UmmbPrvTI:fBbmrch4q4w:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=a0UmmbPrvTI:fBbmrch4q4w:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=a0UmmbPrvTI:fBbmrch4q4w:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=a0UmmbPrvTI:fBbmrch4q4w:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/a0UmmbPrvTI" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/06/cancer-clinical-trials-and-treatments.htmltag:blogger.com,1999:blog-6278250556678332358.post-3487101377810117197Tue, 28 Jun 2011 10:34:00 +00002011-06-28T06:34:43.361-04:00Life TechnologiesBeijing Genomics InstituteEscherichia coli O157:H7Escherichia coliRobert Koch InstituteGermanyImage via WikipediaAs of June 15, the number of people who were ill due to the outbreak of a new E. coli strain in Europe had reached 3,244, according to the Associated Press (AP). Most of the reports have been in Germany, and 784 of the total had developed a serious complication that could lead to kidney failure. AP reported that 37 people have died in Germany, and one person died in Swedenhttp://feedproxy.google.com/~r/BioPharmaInvestor/~3/W_f3eUE2HrE/killer-e-coli-strain-identified-in.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/9HNqkHtk8HC9TwNAB_QpZ9S0ors/0/da"><img src="http://feedads.g.doubleclick.net/~a/9HNqkHtk8HC9TwNAB_QpZ9S0ors/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/9HNqkHtk8HC9TwNAB_QpZ9S0ors/1/da"><img src="http://feedads.g.doubleclick.net/~a/9HNqkHtk8HC9TwNAB_QpZ9S0ors/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=W_f3eUE2HrE:pjgYrB_NUQc:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=W_f3eUE2HrE:pjgYrB_NUQc:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=W_f3eUE2HrE:pjgYrB_NUQc:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=W_f3eUE2HrE:pjgYrB_NUQc:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=W_f3eUE2HrE:pjgYrB_NUQc:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=W_f3eUE2HrE:pjgYrB_NUQc:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=W_f3eUE2HrE:pjgYrB_NUQc:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=W_f3eUE2HrE:pjgYrB_NUQc:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=W_f3eUE2HrE:pjgYrB_NUQc:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/W_f3eUE2HrE" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/06/killer-e-coli-strain-identified-in.htmltag:blogger.com,1999:blog-6278250556678332358.post-438877753141630600Tue, 28 Jun 2011 10:22:00 +00002011-06-28T06:22:50.000-04:00Clinical TrialsPsoriasisAnacor PharmaceuticalsImage via Wikipedia Anacor Pharmaceuticals (NASDAQ:ANAC) announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis. The trial enrolled 68 subjects randomized in a 2:1 ratio, AN2728 to vehicle. Subjects treated with AN2728 showed improvement over vehicle at each of the recorded timepoints http://feedproxy.google.com/~r/BioPharmaInvestor/~3/r-nAmv4Jsb4/anacor-pharmaceuticals-and-psoriasis.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/NnBhNT9vRV2vHtqKe3yHhVUK5Ig/0/da"><img src="http://feedads.g.doubleclick.net/~a/NnBhNT9vRV2vHtqKe3yHhVUK5Ig/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/NnBhNT9vRV2vHtqKe3yHhVUK5Ig/1/da"><img src="http://feedads.g.doubleclick.net/~a/NnBhNT9vRV2vHtqKe3yHhVUK5Ig/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=r-nAmv4Jsb4:EQnZlTUccZE:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=r-nAmv4Jsb4:EQnZlTUccZE:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=r-nAmv4Jsb4:EQnZlTUccZE:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=r-nAmv4Jsb4:EQnZlTUccZE:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=r-nAmv4Jsb4:EQnZlTUccZE:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=r-nAmv4Jsb4:EQnZlTUccZE:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=r-nAmv4Jsb4:EQnZlTUccZE:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=r-nAmv4Jsb4:EQnZlTUccZE:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=r-nAmv4Jsb4:EQnZlTUccZE:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/r-nAmv4Jsb4" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/06/anacor-pharmaceuticals-and-psoriasis.htmltag:blogger.com,1999:blog-6278250556678332358.post-3665980476377409925Tue, 28 Jun 2011 10:09:00 +00002011-06-28T06:10:41.354-04:00AmgenXGEVAFood and Drug AdministrationOlivia Newton-JohnBone metastasisBiologic License ApplicationProstate cancerDenosumabGlaxoSmithKlineImage via WikipediaTHOUSAND OAKS, Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, http://feedproxy.google.com/~r/BioPharmaInvestor/~3/rXNzb8_Q6bY/amgen-submits-bla-for-xgeva.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/jXTh9nwGQfmyFiwuyPsAzVNeL1E/0/da"><img src="http://feedads.g.doubleclick.net/~a/jXTh9nwGQfmyFiwuyPsAzVNeL1E/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/jXTh9nwGQfmyFiwuyPsAzVNeL1E/1/da"><img src="http://feedads.g.doubleclick.net/~a/jXTh9nwGQfmyFiwuyPsAzVNeL1E/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rXNzb8_Q6bY:ev-Q28sTuPc:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rXNzb8_Q6bY:ev-Q28sTuPc:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=rXNzb8_Q6bY:ev-Q28sTuPc:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rXNzb8_Q6bY:ev-Q28sTuPc:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rXNzb8_Q6bY:ev-Q28sTuPc:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rXNzb8_Q6bY:ev-Q28sTuPc:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=rXNzb8_Q6bY:ev-Q28sTuPc:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rXNzb8_Q6bY:ev-Q28sTuPc:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rXNzb8_Q6bY:ev-Q28sTuPc:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/rXNzb8_Q6bY" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/06/amgen-submits-bla-for-xgeva.htmltag:blogger.com,1999:blog-6278250556678332358.post-2649603836994854318Tue, 28 Jun 2011 10:04:00 +00002011-06-28T06:04:28.695-04:00Food and Drug AdministrationLung cancerPfizerCrizotinibClinical trialAnaplastic lymphoma kinasecancerNon-small cell lung carcinomaImage via CrunchBase Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 (PF-299) an investigational, oral, pan-HER inhibitor;1 and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK,2 at the International Association for the Study of Lung http://feedproxy.google.com/~r/BioPharmaInvestor/~3/iATWUBN1EG0/pfizers-to-present-lung-cancer-data.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/mlwIgEyZfH_0NGbkHwtCIyjPNhU/0/da"><img src="http://feedads.g.doubleclick.net/~a/mlwIgEyZfH_0NGbkHwtCIyjPNhU/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/mlwIgEyZfH_0NGbkHwtCIyjPNhU/1/da"><img src="http://feedads.g.doubleclick.net/~a/mlwIgEyZfH_0NGbkHwtCIyjPNhU/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=iATWUBN1EG0:Md3abPQ3H2M:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=iATWUBN1EG0:Md3abPQ3H2M:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=iATWUBN1EG0:Md3abPQ3H2M:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=iATWUBN1EG0:Md3abPQ3H2M:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=iATWUBN1EG0:Md3abPQ3H2M:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=iATWUBN1EG0:Md3abPQ3H2M:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=iATWUBN1EG0:Md3abPQ3H2M:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=iATWUBN1EG0:Md3abPQ3H2M:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=iATWUBN1EG0:Md3abPQ3H2M:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/iATWUBN1EG0" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/06/pfizers-to-present-lung-cancer-data.htmltag:blogger.com,1999:blog-6278250556678332358.post-6299789461760734205Tue, 28 Jun 2011 09:50:00 +00002011-06-28T06:15:02.450-04:00Boehringer IngelheimAstraZenecaType 2 DiabetesEli LillyBristol-Myers SquibbNovo NordiskInsulinADA meetingtype 1 diabetesDiabetes mellitus type 1Image via WikipediaGEN | News Highlights:Firms Report Promising Data for Type 1 and 2 Diabetes Candidates at 71st Annual ADA Meeting The American Diabetes Association (ADA) meeting in San Diego included the presentation of new data from Phase III trials evaluating Bristol-Myers Squibb (BMS) and AstraZeneca’s dapagliflozin, Boehringer Ingelheim and Eli Lilly’s linagliptin, and Novo Nordisk’s http://feedproxy.google.com/~r/BioPharmaInvestor/~3/RTMbIO1584g/gen-news-highlightsfirms-report.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/23gVvdCNUHyvSUWIcYLXrOjvByk/0/da"><img src="http://feedads.g.doubleclick.net/~a/23gVvdCNUHyvSUWIcYLXrOjvByk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/23gVvdCNUHyvSUWIcYLXrOjvByk/1/da"><img src="http://feedads.g.doubleclick.net/~a/23gVvdCNUHyvSUWIcYLXrOjvByk/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=RTMbIO1584g:ALytNa72bho:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=RTMbIO1584g:ALytNa72bho:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=RTMbIO1584g:ALytNa72bho:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=RTMbIO1584g:ALytNa72bho:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=RTMbIO1584g:ALytNa72bho:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=RTMbIO1584g:ALytNa72bho:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=RTMbIO1584g:ALytNa72bho:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=RTMbIO1584g:ALytNa72bho:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=RTMbIO1584g:ALytNa72bho:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/RTMbIO1584g" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/06/gen-news-highlightsfirms-report.htmltag:blogger.com,1999:blog-6278250556678332358.post-1670255955973210067Tue, 28 Jun 2011 09:47:00 +00002011-06-28T05:49:29.815-04:00ePROClinical TrialsJohns HopkinsPublic HealthCROCloud ComputingGEN | Analysis & Insight: Cloud Computing Augments Clinical Trial Process (Page 1 of 1)Pharma and biotech companies have so far tended to use cloud computing services for drug development research, not clinical trials. IBM and other smaller tech companies would like to change all that, though. Additionally, applying cloud computing for data analysis to aid patient http://feedproxy.google.com/~r/BioPharmaInvestor/~3/bb6-QqSlax8/gen-analysis-insight-cloud-computing.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/5Bpop6FcAwcsQGqk1PWsaUlPYaY/0/da"><img src="http://feedads.g.doubleclick.net/~a/5Bpop6FcAwcsQGqk1PWsaUlPYaY/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/5Bpop6FcAwcsQGqk1PWsaUlPYaY/1/da"><img src="http://feedads.g.doubleclick.net/~a/5Bpop6FcAwcsQGqk1PWsaUlPYaY/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=bb6-QqSlax8:EoJSd0INLmA:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=bb6-QqSlax8:EoJSd0INLmA:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=bb6-QqSlax8:EoJSd0INLmA:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=bb6-QqSlax8:EoJSd0INLmA:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=bb6-QqSlax8:EoJSd0INLmA:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=bb6-QqSlax8:EoJSd0INLmA:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=bb6-QqSlax8:EoJSd0INLmA:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=bb6-QqSlax8:EoJSd0INLmA:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=bb6-QqSlax8:EoJSd0INLmA:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/bb6-QqSlax8" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/06/gen-analysis-insight-cloud-computing.htmltag:blogger.com,1999:blog-6278250556678332358.post-703553308263513971Thu, 02 Jun 2011 09:28:00 +00002011-06-02T06:22:20.101-04:00HPV cancerCervical cancerHPV Oral CancerMerckMens CancerHuman papillomavirusMRKGardasilHPVHead and neck cancerThroat Cancer Linked to HPV By LAURA LANDRO A sharp rise in a type of throat cancer among men is increasingly being linked to HPV, the sexually transmitted human papillomavirus that can cause cervical cancer in women. A new study from the National Cancer Institute warns that if recent trends continue, the number of HPV-positive oral cancers among men could rise by nearly 30% by 2020. At thathttp://feedproxy.google.com/~r/BioPharmaInvestor/~3/30uwC2R-ybM/recent-news-concerning-hpv-in-men-hpv.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/Dmmvm5qj0jta8xX0VysVEggEnMo/0/da"><img src="http://feedads.g.doubleclick.net/~a/Dmmvm5qj0jta8xX0VysVEggEnMo/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/Dmmvm5qj0jta8xX0VysVEggEnMo/1/da"><img src="http://feedads.g.doubleclick.net/~a/Dmmvm5qj0jta8xX0VysVEggEnMo/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=30uwC2R-ybM:EfkkwEmBHWg:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=30uwC2R-ybM:EfkkwEmBHWg:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=30uwC2R-ybM:EfkkwEmBHWg:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=30uwC2R-ybM:EfkkwEmBHWg:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=30uwC2R-ybM:EfkkwEmBHWg:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=30uwC2R-ybM:EfkkwEmBHWg:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=30uwC2R-ybM:EfkkwEmBHWg:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=30uwC2R-ybM:EfkkwEmBHWg:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=30uwC2R-ybM:EfkkwEmBHWg:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/30uwC2R-ybM" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/06/recent-news-concerning-hpv-in-men-hpv.htmltag:blogger.com,1999:blog-6278250556678332358.post-3773103493845998214Sun, 27 Mar 2011 03:18:00 +00002011-03-26T23:18:57.374-04:00melanoma drugFood and Drug AdministrationMelanomaBristol-Myers SquibbThomson ReutersIpilimumabClinical trialBristolcancer By Bill BerkrotNEW YORK | Mon Mar 21, 2011 6:37pm EDT (Reuters) - Bristol-Myers Squibb Co's eagerly anticipated experimental drug ipilimumab extended survival of previously untreated patients with advanced melanoma in a late stage study, the company said. Details of how much longer patients who were suffering from the deadly skin cancer lived after taking the http://feedproxy.google.com/~r/BioPharmaInvestor/~3/rh8Ah70fD3Y/bristol-melanoma-drug-extends-survival.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/jcmkYJYelOGkP3UZ9RN7jL0c68M/0/da"><img src="http://feedads.g.doubleclick.net/~a/jcmkYJYelOGkP3UZ9RN7jL0c68M/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/jcmkYJYelOGkP3UZ9RN7jL0c68M/1/da"><img src="http://feedads.g.doubleclick.net/~a/jcmkYJYelOGkP3UZ9RN7jL0c68M/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rh8Ah70fD3Y:jswq77qiN3U:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rh8Ah70fD3Y:jswq77qiN3U:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=rh8Ah70fD3Y:jswq77qiN3U:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rh8Ah70fD3Y:jswq77qiN3U:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rh8Ah70fD3Y:jswq77qiN3U:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rh8Ah70fD3Y:jswq77qiN3U:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=rh8Ah70fD3Y:jswq77qiN3U:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rh8Ah70fD3Y:jswq77qiN3U:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=rh8Ah70fD3Y:jswq77qiN3U:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/rh8Ah70fD3Y" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/03/bristol-melanoma-drug-extends-survival.htmltag:blogger.com,1999:blog-6278250556678332358.post-7698094583486322115Sun, 27 Mar 2011 02:39:00 +00002011-03-26T23:07:50.740-04:00Howard Hughes Medical InstituteBroad InstituteBRAFMultiple Myeloma Research FoundationGenome StudyCancer ResearchBlood cancerDana–Farber Cancer InstituteDaiichi SankyoTodd Golub Bio Technician demonstrates the loading of the high tech 454 Life Science sequencing machine in the sequencing laboratory at the J. Craig Venter Institute in Rockville, Maryland, in this March 29, 2010 file photo. Credit: Reuters/Larry Downing (UNITED STATES - Tags: SCI TECH) Image via Wikipedia(Reuters) -  By Julie SteenhuysenCHICAGO | Wed Mar 23, 2011 2:17pm EDT   http://feedproxy.google.com/~r/BioPharmaInvestor/~3/Ib5xUBs0IGo/genome-study-brings-blood-cancer-into.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/_cVs_X_0KkMzaAbZIwickEzKeSs/0/da"><img src="http://feedads.g.doubleclick.net/~a/_cVs_X_0KkMzaAbZIwickEzKeSs/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/_cVs_X_0KkMzaAbZIwickEzKeSs/1/da"><img src="http://feedads.g.doubleclick.net/~a/_cVs_X_0KkMzaAbZIwickEzKeSs/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Ib5xUBs0IGo:I6GmTv1Abfg:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Ib5xUBs0IGo:I6GmTv1Abfg:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=Ib5xUBs0IGo:I6GmTv1Abfg:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Ib5xUBs0IGo:I6GmTv1Abfg:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Ib5xUBs0IGo:I6GmTv1Abfg:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Ib5xUBs0IGo:I6GmTv1Abfg:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=Ib5xUBs0IGo:I6GmTv1Abfg:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Ib5xUBs0IGo:I6GmTv1Abfg:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Ib5xUBs0IGo:I6GmTv1Abfg:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/Ib5xUBs0IGo" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/03/genome-study-brings-blood-cancer-into.htmltag:blogger.com,1999:blog-6278250556678332358.post-142767099830871024Mon, 31 Jan 2011 02:09:00 +00002011-01-30T21:10:19.741-05:00PerkinElmerDr. VenterPKIJ. Craig Venter InstituteJ. Craig VenterDNAHuman Genome ProjectGeneticsTranscription (genetics)DNA sequencingCraig VenterImage via Wikipedia Perkins Elmer has an extensive history in the genomic sequencing field and Dr. Craig Venter. Dr. Venter is a former researcher for The Institute for Genomic Research and founded the J. Craig Venter Institute.  Find out more  here:  http://www.jcvi.org/ Google finance:  NYSE:PKI PerkinElmer Website PerkinElmer Enters DNA Sequencing Market By MATTHEW HERPER PerkinElmer http://feedproxy.google.com/~r/BioPharmaInvestor/~3/Hkv58n23HY0/perkinselmer-genomic-sequencing-history.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/9Z67OIFXNKh1YePKPKYElK6uLx4/0/da"><img src="http://feedads.g.doubleclick.net/~a/9Z67OIFXNKh1YePKPKYElK6uLx4/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/9Z67OIFXNKh1YePKPKYElK6uLx4/1/da"><img src="http://feedads.g.doubleclick.net/~a/9Z67OIFXNKh1YePKPKYElK6uLx4/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Hkv58n23HY0:A_3Zl8b1Bac:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Hkv58n23HY0:A_3Zl8b1Bac:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=Hkv58n23HY0:A_3Zl8b1Bac:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Hkv58n23HY0:A_3Zl8b1Bac:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Hkv58n23HY0:A_3Zl8b1Bac:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Hkv58n23HY0:A_3Zl8b1Bac:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=Hkv58n23HY0:A_3Zl8b1Bac:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Hkv58n23HY0:A_3Zl8b1Bac:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Hkv58n23HY0:A_3Zl8b1Bac:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/Hkv58n23HY0" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/perkinselmer-genomic-sequencing-history.htmltag:blogger.com,1999:blog-6278250556678332358.post-6933102997665664040Fri, 28 Jan 2011 03:05:00 +00002011-01-27T22:05:17.896-05:00VilazodoneBiotechnology StocksTop Rated Stocks: BiotechnologyClinical DataMajor depressive disorderCLDATop Biotech StocksAntidepressantImage via Wikipedia Top Rated Stocks: BiotechnologyTop Rated Stocks 01/27/11 Clinical Data Website Clinical Data Pipeline Clinical Data--Google Finance  CLDA January 24, 2011Clinical Data, Inc. Announces FDA Approval of Viibryd™ (vilazodone HCl) for Major Depressive DisorderRSS Feed for Top Rated Stocks: Biotechnology Every day TheStreet Ratings produces a list of the top rated stocks. http://feedproxy.google.com/~r/BioPharmaInvestor/~3/pIQCTuV8X90/top-rated-biotechnolgy-stocks-street.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/PgnkwRapOaQbXdrrZYh0zabSs7E/0/da"><img src="http://feedads.g.doubleclick.net/~a/PgnkwRapOaQbXdrrZYh0zabSs7E/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/PgnkwRapOaQbXdrrZYh0zabSs7E/1/da"><img src="http://feedads.g.doubleclick.net/~a/PgnkwRapOaQbXdrrZYh0zabSs7E/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=pIQCTuV8X90:4cWLUR6Fi1M:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=pIQCTuV8X90:4cWLUR6Fi1M:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=pIQCTuV8X90:4cWLUR6Fi1M:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=pIQCTuV8X90:4cWLUR6Fi1M:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=pIQCTuV8X90:4cWLUR6Fi1M:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=pIQCTuV8X90:4cWLUR6Fi1M:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=pIQCTuV8X90:4cWLUR6Fi1M:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=pIQCTuV8X90:4cWLUR6Fi1M:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=pIQCTuV8X90:4cWLUR6Fi1M:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/pIQCTuV8X90" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/top-rated-biotechnolgy-stocks-street.htmltag:blogger.com,1999:blog-6278250556678332358.post-7407467632640696781Thu, 27 Jan 2011 22:17:00 +00002011-01-27T21:27:21.488-05:00MNKDPDLISVNTNVSTags: BIIBILMNMRKCLDAALXNLLYPFEOPXAAMGNBMYTop BioHealth Research Calls of the Week (MNKD, PDLI, ILMN, CLDA, MRK, PFE, LLY, BMY, ALXN, SVNT, AMGN) January 22, 2011 · Filed Under Financial, analyst calls, fda · Comment  There were some key research calls in biotech and biohealth shares this week.  Over in our “top five analyst calls of the week” at 24/7 Wall Street we noted how one firm came out in defense of MannKind Corporation (NASDAQ:http://feedproxy.google.com/~r/BioPharmaInvestor/~3/h6KOIhvil8s/top-biohealth-investor-calls-of-month.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/PG8hebwWulOUVCAxd05h4oe_4J0/0/da"><img src="http://feedads.g.doubleclick.net/~a/PG8hebwWulOUVCAxd05h4oe_4J0/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/PG8hebwWulOUVCAxd05h4oe_4J0/1/da"><img src="http://feedads.g.doubleclick.net/~a/PG8hebwWulOUVCAxd05h4oe_4J0/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=h6KOIhvil8s:By1LTOXBi_E:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=h6KOIhvil8s:By1LTOXBi_E:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=h6KOIhvil8s:By1LTOXBi_E:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=h6KOIhvil8s:By1LTOXBi_E:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=h6KOIhvil8s:By1LTOXBi_E:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=h6KOIhvil8s:By1LTOXBi_E:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=h6KOIhvil8s:By1LTOXBi_E:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=h6KOIhvil8s:By1LTOXBi_E:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=h6KOIhvil8s:By1LTOXBi_E:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/h6KOIhvil8s" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/top-biohealth-investor-calls-of-month.htmltag:blogger.com,1999:blog-6278250556678332358.post-434115504725088984Fri, 14 Jan 2011 03:34:00 +00002011-01-27T21:14:55.737-05:00MNKDInhalable insulinInsulinMannKind CorporationClinical trialAfrezzaNew Drug ApplicationDiabetes mellitusAlfred MannBiotech and Pharmaceutical news:  Mannkind (MNKD) Google Finance:  MNKD Mannkind Corp.  Website Mannkind Pipeline I am cautious about Mannkind's approval chances with the FDA in the next coming weeks (FDA delayed Dec 29th decision 4 weeks) but I am optimistic about its chances of an increase in stock price while the FDA reviews Mannkind's approval for Afrezza for Diabetes.  Here are some news http://feedproxy.google.com/~r/BioPharmaInvestor/~3/KaY4LLIQ-Kw/mannkind-is-having-increased-momentum.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/JNfPYuyydFZiMzj7kF7IrfHNTfE/0/da"><img src="http://feedads.g.doubleclick.net/~a/JNfPYuyydFZiMzj7kF7IrfHNTfE/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/JNfPYuyydFZiMzj7kF7IrfHNTfE/1/da"><img src="http://feedads.g.doubleclick.net/~a/JNfPYuyydFZiMzj7kF7IrfHNTfE/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=KaY4LLIQ-Kw:05v9gDtP8r0:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=KaY4LLIQ-Kw:05v9gDtP8r0:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=KaY4LLIQ-Kw:05v9gDtP8r0:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=KaY4LLIQ-Kw:05v9gDtP8r0:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=KaY4LLIQ-Kw:05v9gDtP8r0:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=KaY4LLIQ-Kw:05v9gDtP8r0:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=KaY4LLIQ-Kw:05v9gDtP8r0:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=KaY4LLIQ-Kw:05v9gDtP8r0:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=KaY4LLIQ-Kw:05v9gDtP8r0:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/KaY4LLIQ-Kw" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/mannkind-is-having-increased-momentum.htmltag:blogger.com,1999:blog-6278250556678332358.post-9063548931279366979Wed, 12 Jan 2011 05:42:00 +00002011-01-12T00:47:16.922-05:00Pancreatic cancerBavituximabHepatitis C virusClinical TrialsPeregrine PharmaceuticalsAntiviralPPHM Hepatitis C Virus Image via Wikipedia Peregrine seems poised for growth in 2011 Written by Patrick Crutcher Tuesday, 11 January 2011 Zacks.com Profile:  PPHM Peregrine Pharmaceutical Pipeline Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that it has initiated several trials in oncology and viral infections. They seem poised to garner attention from the Street over the coming http://feedproxy.google.com/~r/BioPharmaInvestor/~3/B39SD-ZCjFc/another-2011-standout-peregrine.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/OMmNDp_krlfnMPVVXZz5qsNoqvk/0/da"><img src="http://feedads.g.doubleclick.net/~a/OMmNDp_krlfnMPVVXZz5qsNoqvk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/OMmNDp_krlfnMPVVXZz5qsNoqvk/1/da"><img src="http://feedads.g.doubleclick.net/~a/OMmNDp_krlfnMPVVXZz5qsNoqvk/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=B39SD-ZCjFc:Xf7MuHS_SPY:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=B39SD-ZCjFc:Xf7MuHS_SPY:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=B39SD-ZCjFc:Xf7MuHS_SPY:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=B39SD-ZCjFc:Xf7MuHS_SPY:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=B39SD-ZCjFc:Xf7MuHS_SPY:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=B39SD-ZCjFc:Xf7MuHS_SPY:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=B39SD-ZCjFc:Xf7MuHS_SPY:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=B39SD-ZCjFc:Xf7MuHS_SPY:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=B39SD-ZCjFc:Xf7MuHS_SPY:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/B39SD-ZCjFc" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/another-2011-standout-peregrine.htmltag:blogger.com,1999:blog-6278250556678332358.post-1056870641270805235Wed, 12 Jan 2011 02:17:00 +00002011-01-27T21:17:41.012-05:00Human Genome SciencesDendreonEli LillyDepomedSpectrum PharmaceuticalsBiotech StocksTop Biotech StocksJanuary CatalystsBiotech 2011Seattle GeneticsStocks Mentioned:  Dendreon, Human Genome Sciences, Eli Lilly, Cerus, Curis, Compugen, Spectrum Pharmaceuticals, Impax Laboratories, Exelixis, Medivation, Seattle Genetics, Corcept, PolyMedix, BioMarin, Endo Pharmaceuticals, DepoMed, Mannkind, Orexigen Therapeutics, AstraZeneca, Clinical Data Here are the Top Biotech Picks for 2011, Stocks Highlighted at the JP Morgan Healthcare Conference, Newshttp://feedproxy.google.com/~r/BioPharmaInvestor/~3/Q_0EqKPLb9c/top-biotech-stocks-for-2011-and-january.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/r18OmgJKRYDON_1vcwzF3GUK4yg/0/da"><img src="http://feedads.g.doubleclick.net/~a/r18OmgJKRYDON_1vcwzF3GUK4yg/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/r18OmgJKRYDON_1vcwzF3GUK4yg/1/da"><img src="http://feedads.g.doubleclick.net/~a/r18OmgJKRYDON_1vcwzF3GUK4yg/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Q_0EqKPLb9c:JBfAudgtkog:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Q_0EqKPLb9c:JBfAudgtkog:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=Q_0EqKPLb9c:JBfAudgtkog:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Q_0EqKPLb9c:JBfAudgtkog:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Q_0EqKPLb9c:JBfAudgtkog:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Q_0EqKPLb9c:JBfAudgtkog:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=Q_0EqKPLb9c:JBfAudgtkog:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Q_0EqKPLb9c:JBfAudgtkog:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=Q_0EqKPLb9c:JBfAudgtkog:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/Q_0EqKPLb9c" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/top-biotech-stocks-for-2011-and-january.htmltag:blogger.com,1999:blog-6278250556678332358.post-8477326727243078175Tue, 11 Jan 2011 02:49:00 +00002011-01-10T21:52:50.677-05:00CystinosisBiotechnology and PharmaceuticalsRaptor PharmaceuticalsRPTPRare diseaseCysteamine Image via Wikipedia Interest for Raptor Pharmaceuticals is really picking up in 2011.  Here are the recent headlines for this up and coming Small Cap Pharmaceutical company.  It has a Pipeline for Rare Diseases and I expect 2011 to be a strong year for Raptor Pharmaceuticals if Clinical Trial results are successful.  Results for DR Cysteamine clinical trials is expected in 1Q 2011.  DRhttp://feedproxy.google.com/~r/BioPharmaInvestor/~3/lDhnbCPGjAU/raptor-pharmaceuticals-in-2011.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/xQnugLX6ufzTcf3AdVjSjS7LIXk/0/da"><img src="http://feedads.g.doubleclick.net/~a/xQnugLX6ufzTcf3AdVjSjS7LIXk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/xQnugLX6ufzTcf3AdVjSjS7LIXk/1/da"><img src="http://feedads.g.doubleclick.net/~a/xQnugLX6ufzTcf3AdVjSjS7LIXk/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=lDhnbCPGjAU:sWMtvOYHMZA:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=lDhnbCPGjAU:sWMtvOYHMZA:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=lDhnbCPGjAU:sWMtvOYHMZA:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=lDhnbCPGjAU:sWMtvOYHMZA:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=lDhnbCPGjAU:sWMtvOYHMZA:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=lDhnbCPGjAU:sWMtvOYHMZA:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=lDhnbCPGjAU:sWMtvOYHMZA:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=lDhnbCPGjAU:sWMtvOYHMZA:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=lDhnbCPGjAU:sWMtvOYHMZA:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/lDhnbCPGjAU" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/raptor-pharmaceuticals-in-2011.htmltag:blogger.com,1999:blog-6278250556678332358.post-8263461449575314042Sat, 08 Jan 2011 09:01:00 +00002011-01-08T04:01:25.737-05:00ViroproFood and Drug AdministrationColorectal cancerchemotherapyRocheClinical trialSPPISpectrum PharmaceuticalsNew Drug ApplicationSpectrum Pharmaceuticals Submits Supplemental New Drug Application (sNDA) For Ready-to-Use Formulation Of FUSILEV(R) In Colorectal Cancer Main Category: Colorectal Cancer Also Included In: Cancer / Oncology Article Date: 06 Jan 2011 - 1:00 PST Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus http://feedproxy.google.com/~r/BioPharmaInvestor/~3/UjPXDw8dOaU/spectrum-pharmaceuticals-is-making.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/zyIMIwQcpybikapzc6gViY9G_8k/0/da"><img src="http://feedads.g.doubleclick.net/~a/zyIMIwQcpybikapzc6gViY9G_8k/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/zyIMIwQcpybikapzc6gViY9G_8k/1/da"><img src="http://feedads.g.doubleclick.net/~a/zyIMIwQcpybikapzc6gViY9G_8k/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=UjPXDw8dOaU:hy7lqLnKQfg:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=UjPXDw8dOaU:hy7lqLnKQfg:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=UjPXDw8dOaU:hy7lqLnKQfg:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=UjPXDw8dOaU:hy7lqLnKQfg:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=UjPXDw8dOaU:hy7lqLnKQfg:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=UjPXDw8dOaU:hy7lqLnKQfg:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=UjPXDw8dOaU:hy7lqLnKQfg:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=UjPXDw8dOaU:hy7lqLnKQfg:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=UjPXDw8dOaU:hy7lqLnKQfg:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/UjPXDw8dOaU" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/spectrum-pharmaceuticals-is-making.htmltag:blogger.com,1999:blog-6278250556678332358.post-4170797708099245269Sat, 08 Jan 2011 02:13:00 +00002011-01-07T21:13:06.922-05:00DendreonJP Morgan Healthcare Conference2011 Biotech PreviewJP Morgan Healthcare Conference 2011 Preview Stocks Mentioned:  AMAG, AMGN, AMLN, ARIA, CELG, DNDN, GENZ, GILD, HGSI, ITMN, KERX, MNKD, NKTR, OREX, SGEN, SNY, SVNT, TEVA, VRTX, VVUS, MRK The Street: Biotech 2011 Kickoff Party Investor Preview By: Adam Feuerstein The biotech industry descends on the City by the Bay starting Sunday for a week of investor meetings, networking, deal making and http://feedproxy.google.com/~r/BioPharmaInvestor/~3/uq735HqnByg/2011-biotech-preview-jp-morgan.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/1nnJ9XCFbuzFs_W0UkIJxorXR_Q/0/da"><img src="http://feedads.g.doubleclick.net/~a/1nnJ9XCFbuzFs_W0UkIJxorXR_Q/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/1nnJ9XCFbuzFs_W0UkIJxorXR_Q/1/da"><img src="http://feedads.g.doubleclick.net/~a/1nnJ9XCFbuzFs_W0UkIJxorXR_Q/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=uq735HqnByg:LZylNsKN02Q:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=uq735HqnByg:LZylNsKN02Q:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=uq735HqnByg:LZylNsKN02Q:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=uq735HqnByg:LZylNsKN02Q:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=uq735HqnByg:LZylNsKN02Q:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=uq735HqnByg:LZylNsKN02Q:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=uq735HqnByg:LZylNsKN02Q:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=uq735HqnByg:LZylNsKN02Q:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=uq735HqnByg:LZylNsKN02Q:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/uq735HqnByg" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/2011-biotech-preview-jp-morgan.htmltag:blogger.com,1999:blog-6278250556678332358.post-3866264903144043470Thu, 06 Jan 2011 08:45:00 +00002011-01-06T03:45:06.576-05:00Sorry for any delays.  I was out of town for the past month and was not able to keep up with the website.  The website will be back up and running in the next few days with new BioPharma News and Articles.  Again I apologize for a lack of quality posts last month, but again I will be working diligently throughout this year to provide the most up to date news and information on the hottest http://feedproxy.google.com/~r/BioPharmaInvestor/~3/j-V_m_t6WtI/biopharma-investor-is-back-in-business.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/hX57UaqF25gg3evnEVFRDPxpqM4/0/da"><img src="http://feedads.g.doubleclick.net/~a/hX57UaqF25gg3evnEVFRDPxpqM4/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/hX57UaqF25gg3evnEVFRDPxpqM4/1/da"><img src="http://feedads.g.doubleclick.net/~a/hX57UaqF25gg3evnEVFRDPxpqM4/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=j-V_m_t6WtI:ubuMXmH8kE8:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=j-V_m_t6WtI:ubuMXmH8kE8:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=j-V_m_t6WtI:ubuMXmH8kE8:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=j-V_m_t6WtI:ubuMXmH8kE8:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=j-V_m_t6WtI:ubuMXmH8kE8:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=j-V_m_t6WtI:ubuMXmH8kE8:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=j-V_m_t6WtI:ubuMXmH8kE8:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=j-V_m_t6WtI:ubuMXmH8kE8:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=j-V_m_t6WtI:ubuMXmH8kE8:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/j-V_m_t6WtI" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2011/01/biopharma-investor-is-back-in-business.htmltag:blogger.com,1999:blog-6278250556678332358.post-2442884374355923621Fri, 19 Nov 2010 02:32:00 +00002010-11-18T21:33:24.306-05:00Clinical TrialsClinical trialAastrom BiosciencesReutersPhase IIASTMStem CellsCritical Limb Ischemia Good and Bad news for Aastrom Biosciences today.  Shares dropped heavily after Reuters reports that Aastrom's potential stem cell therapy did not meet a secondary endpoint for it's Phase II clinical trial for the treatment of Critical Limb Ischemia which can cause amputation in those who suffer from the disease.  I have seen this a few times lately, where a stock receives generally positive newshttp://feedproxy.google.com/~r/BioPharmaInvestor/~3/FKECBVRMCTw/aastrom-announces-phase-ii-clinical.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/DT57yqbtvFIlrmGIq7ARSGXersM/0/da"><img src="http://feedads.g.doubleclick.net/~a/DT57yqbtvFIlrmGIq7ARSGXersM/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/DT57yqbtvFIlrmGIq7ARSGXersM/1/da"><img src="http://feedads.g.doubleclick.net/~a/DT57yqbtvFIlrmGIq7ARSGXersM/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=FKECBVRMCTw:rj5trmn3UCA:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=FKECBVRMCTw:rj5trmn3UCA:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=FKECBVRMCTw:rj5trmn3UCA:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=FKECBVRMCTw:rj5trmn3UCA:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=FKECBVRMCTw:rj5trmn3UCA:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=FKECBVRMCTw:rj5trmn3UCA:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=FKECBVRMCTw:rj5trmn3UCA:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=FKECBVRMCTw:rj5trmn3UCA:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=FKECBVRMCTw:rj5trmn3UCA:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/FKECBVRMCTw" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2010/11/aastrom-announces-phase-ii-clinical.htmltag:blogger.com,1999:blog-6278250556678332358.post-5614788055297751206Thu, 18 Nov 2010 16:01:00 +00002010-11-18T18:16:16.373-05:00Systemic lupus erythematosusFood and Drug AdministrationMarketWatchHuman Genome SciencesBenlystaCitigroupGlaxoSmithKlineBank of America Elmo the Investment Banker is killing traders.  Stick to Sesame Street Elmo.  You aren't cut out for Wall St. Just after Tuesday's FDA Recommendation for Human Genome Sciences' Lupus Therapy Benlysta, Citigroup and Bank of America downgraded the stock.  Obviously, they mistakenly shorted the stocks and wanted to get their money back after guessing wrong on the FDA decision.  The drug was http://feedproxy.google.com/~r/BioPharmaInvestor/~3/xqLtaG7y9SQ/human-genome-sciences-shares-decline.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/5GqrYSAJ2zGEonyL9OmOxrN_aeI/0/da"><img src="http://feedads.g.doubleclick.net/~a/5GqrYSAJ2zGEonyL9OmOxrN_aeI/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/5GqrYSAJ2zGEonyL9OmOxrN_aeI/1/da"><img src="http://feedads.g.doubleclick.net/~a/5GqrYSAJ2zGEonyL9OmOxrN_aeI/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=xqLtaG7y9SQ:LFVqNAF5ENs:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=xqLtaG7y9SQ:LFVqNAF5ENs:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=xqLtaG7y9SQ:LFVqNAF5ENs:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=xqLtaG7y9SQ:LFVqNAF5ENs:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=xqLtaG7y9SQ:LFVqNAF5ENs:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=xqLtaG7y9SQ:LFVqNAF5ENs:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=xqLtaG7y9SQ:LFVqNAF5ENs:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=xqLtaG7y9SQ:LFVqNAF5ENs:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=xqLtaG7y9SQ:LFVqNAF5ENs:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/xqLtaG7y9SQ" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2010/11/human-genome-sciences-shares-decline.htmltag:blogger.com,1999:blog-6278250556678332358.post-6462855030271252430Wed, 17 Nov 2010 02:49:00 +00002010-11-16T21:55:27.105-05:00HGSIFDA RecommendationHuman Genome SciencesGSKFDABelimumabGlaxo SmithKlineBenlystaLupus Foundation of AmericaLupusGood news today for Human Genome Sciences and those who suffer from Lupus.  FDA voted in favor of Benlysta with a strong vote of 13-2.  Although the FDA doesn't always approve drugs that are recommended by the panel, many times they do, and more so with an Approval Recommendation than without one.  Shares of Human Genome Sciences were up 10.51% to 28.60 in afterhours trading.  Trading was halted http://feedproxy.google.com/~r/BioPharmaInvestor/~3/8eVE2xU92Vk/human-genome-sciences-gains-fda.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/JFCK3ea0CO55S6jkuUpBPk37Zmw/0/da"><img src="http://feedads.g.doubleclick.net/~a/JFCK3ea0CO55S6jkuUpBPk37Zmw/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/JFCK3ea0CO55S6jkuUpBPk37Zmw/1/da"><img src="http://feedads.g.doubleclick.net/~a/JFCK3ea0CO55S6jkuUpBPk37Zmw/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=8eVE2xU92Vk:O_RI26uHwIo:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=8eVE2xU92Vk:O_RI26uHwIo:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=8eVE2xU92Vk:O_RI26uHwIo:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=8eVE2xU92Vk:O_RI26uHwIo:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=8eVE2xU92Vk:O_RI26uHwIo:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=8eVE2xU92Vk:O_RI26uHwIo:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=8eVE2xU92Vk:O_RI26uHwIo:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=8eVE2xU92Vk:O_RI26uHwIo:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=8eVE2xU92Vk:O_RI26uHwIo:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/8eVE2xU92Vk" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2010/11/human-genome-sciences-gains-fda.htmltag:blogger.com,1999:blog-6278250556678332358.post-5046193548640855854Sat, 13 Nov 2010 04:51:00 +00002010-11-13T19:51:13.634-05:00Systemic lupus erythematosusHGSIFDA ReviewHuman Genome SciencesGSKFDA Advisory PanelBenlystaLupus Foundation of AmericaLupusGlaxoSmithKline Purple Walk for Lupus Awareness Everything you need to know about Tuesday's FDA panel recommendation for Human Genome Sciences therapy for Lupus, Benlysta.  If approved Benlysta would be the first approved therapy in 50 years for Lupus.  Friday the FDA released the notes for the upcoming panel review Tuesday, November 16th.  Concerns for the panel Tuesday were an increased risk of suicide, http://feedproxy.google.com/~r/BioPharmaInvestor/~3/ic1vi17ZFcI/tuesdays-fda-panel-review-for-human.htmlnoreply@blogger.com (BioPharma Investor; Troubled Biologist)<p><a href="http://feedads.g.doubleclick.net/~a/uvE2ierrkNQut2i0ty_M_sIwODk/0/da"><img src="http://feedads.g.doubleclick.net/~a/uvE2ierrkNQut2i0ty_M_sIwODk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/uvE2ierrkNQut2i0ty_M_sIwODk/1/da"><img src="http://feedads.g.doubleclick.net/~a/uvE2ierrkNQut2i0ty_M_sIwODk/1/di" border="0" ismap="true"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=ic1vi17ZFcI:YnjpdlEJ9oU:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=ic1vi17ZFcI:YnjpdlEJ9oU:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=ic1vi17ZFcI:YnjpdlEJ9oU:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=ic1vi17ZFcI:YnjpdlEJ9oU:7Q72WNTAKBA"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=7Q72WNTAKBA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=ic1vi17ZFcI:YnjpdlEJ9oU:qj6IDK7rITs"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=qj6IDK7rITs" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=ic1vi17ZFcI:YnjpdlEJ9oU:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?i=ic1vi17ZFcI:YnjpdlEJ9oU:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=ic1vi17ZFcI:YnjpdlEJ9oU:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=I9og5sOYxJI" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/BioPharmaInvestor?a=ic1vi17ZFcI:YnjpdlEJ9oU:dnMXMwOfBR0"><img src="http://feeds.feedburner.com/~ff/BioPharmaInvestor?d=dnMXMwOfBR0" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/ic1vi17ZFcI" height="1" width="1"/>http://biopharmainvestor.blogspot.com/2010/11/tuesdays-fda-panel-review-for-human.htmlhttp://feedproxy.google.com/~r/BioPharmaInvestor/~3/VrKa-UXlquY/meachamrobWed, 19 Aug 2009 00:00:00 PDThttp://del.icio.us/meachamrob#2009-08-18<ul> <li><a href="http://www.google.com/reader/view/">Google Reader.url</a></li> <li><a href="http://www.google.com/reader/view/#overview-page">Google Reader (1000+).url</a></li> <li><a href="http://www.evaluatepharma.com/Default.aspx">EvaluatePharma - Pharma and Biotech forecasting and analysis tool - Home.url</a></li> <li><a href="http://www.covestor.com/mysummary">My Summary - Covestor.url</a></li> </ul><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/VrKa-UXlquY" height="1" width="1"/>http://del.icio.us/meachamrob#2009-08-18http://feedproxy.google.com/~r/BioPharmaInvestor/~3/NuzsFsZV7nc/meachamrobTue, 18 Aug 2009 00:00:00 PDThttp://del.icio.us/meachamrob#2009-08-17<ul> <li><a href="http://pharmexec.findpharma.com/">PharmExec.com Pharmaceutical Executive News.url</a></li> <li><a href="http://technorati.com/">technorati Front Page.url</a></li> <li><a href="http://sethgodin.typepad.com/seths_blog/2006/06/how_to_get_traf.html">Seth's Blog How to get traffic for your blog.url</a></li> <li><a href="http://www.linkreferral.com/accountwel.pl?process=return">Link Referral.url</a></li> </ul><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/NuzsFsZV7nc" height="1" width="1"/>http://del.icio.us/meachamrob#2009-08-17http://feedproxy.google.com/~r/BioPharmaInvestor/~3/3v1FMAvORyc/meachamrobSat, 15 Aug 2009 00:00:00 PDThttp://del.icio.us/meachamrob#2009-08-14<ul> <li><a href="http://www.aetv.com/dog_the_bounty_hunter/featured-artists/">Dog the Bounty Hunter Music Featured Artist.url</a></li> </ul><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/3v1FMAvORyc" height="1" width="1"/>http://del.icio.us/meachamrob#2009-08-14http://feedproxy.google.com/~r/BioPharmaInvestor/~3/ZMFfqKamLpM/meachamrobFri, 14 Aug 2009 00:00:00 PDThttp://del.icio.us/meachamrob#2009-08-13<ul> <li><a href="http://www.linkreferral.com/adwel.pl">http--www.linkreferral.com-adwel.pl.url</a></li> </ul><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/ZMFfqKamLpM" height="1" width="1"/>http://del.icio.us/meachamrob#2009-08-13http://feedproxy.google.com/~r/BioPharmaInvestor/~3/hgO56lGqEFU/meachamrobTue, 11 Aug 2009 00:00:00 PDThttp://del.icio.us/meachamrob#2009-08-10<ul> <li><a href="http://www.apvma.gov.au/guidelines/downloads/gl32_lal.pdf">LAL validation and testing.url</a></li> </ul><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/hgO56lGqEFU" height="1" width="1"/>http://del.icio.us/meachamrob#2009-08-10http://feedproxy.google.com/~r/BioPharmaInvestor/~3/bBkeQTKYuBA/meachamrobMon, 10 Aug 2009 00:00:00 PDThttp://del.icio.us/meachamrob#2009-08-09<ul> <li><a href="http://www.noch.org/uploadedFiles/About_Us/Lab%20Lean.pdf">Lean Lab Benefits.url</a></li> <li><a href="http://microbiology.okstate.edu/faculty/prade/pradelab/PradeLabProtocol.pdf">Molecular Biology Techniques Made Easy-PradeLabProtocol.pdf.url</a></li> <li><a href="http://en.wikipedia.org/wiki/Growth_medium">Selective Media Growth medium - Wikipedia, the free encyclopedia.url</a></li> </ul><img src="http://feeds.feedburner.com/~r/BioPharmaInvestor/~4/bBkeQTKYuBA" height="1" width="1"/>http://del.icio.us/meachamrob#2009-08-09